Review Articles

About Authors:
Shanky Bhat*, Kushal Kandhari
M Phil-Ph.D Scholar
School of Environment and Sustainable Development
Central University of Gujarat,
Sector 30, Gandhinagar, Gujarat 382030
bhatsiya@gmail.com

About Authors:
Ms. Kanika Soni, Ms. Pooja Dhiman*, Mr. Sandeep Singh
Chitkara University, Kalujhanda, Atal Shiksha Kunj,
Barotiwala, Solan [H.P], INDIA
*pooja.dhiman@chitkarauniversity.edu.in

About Authors:
Narinderpal Kaur*, Annapurna Negi, Jyotsna
Assistant Professor
School of Pharmacy and emerging Sciences
Baddi University of Emerging sciences and Technology
Baddi, Himachal Pradesh
*narinder.sonia@gmail.com

About Authors:
Arsh Chanana*, Mahesh Kumar Kataria, Ajay Bilandi
Department of Pharmaceutics, Seth. G.L. Bihani S.D. College of Technical Education,
Sri Ganganagar (Rajasthan) INDIA
*arshchanana806@gmail.com

Abstract-
Microcapsule is a tiny sphere including core material/internal phase or fill, coated with/surrounded by wall know as shell, coating or membrane. The usual size range of the microcapsule lies between 1 to 1000 μm. The technique is usually applied for targeted drug delivery, protection of the molecule and stability if the core material. Microencapsulation system offers potential advantages over conventional drug delivery systems and also established as unique carrier systems for many pharmaceuticals. This article contains the traditional and the recent techniques, including their patents, for the preparation of microcapsules. Solvent exchange method, coacervation, polymerization, hot melts etc are several recent techniques are used for the preparation of the microcapsules. The microencapsulation technique, as Novel drug Delivery System (NDDS), is widely applied for delivery of probiotics, drugs, pesticide, food etc. Although significant advances have been made in the field of microencapsulation, still many challenges need to be rectified during the appropriate selection of core materials, coating materials and process techniques.

ABOUT AUTHOR:
Raj Kishor
Avigna Clinical Research Institute
Bangalore
raryan859@gmail.com

ABOUT AUTHOR:
Rajesh G. Dobariya
shree M.&N. Virani Science College,
Rajkot
drajesh47@gmail.com

ABSTRACT
Single cell protein typically refers to source of mixed protein extracted from pure or mixed culture of algae, yeast, fungi or bacteria. The microbes which are used for single cell protein production must be non-pathogenic to plants, animals and man. Good nutritional value, easily and cheaply produced on scale, toxin free, fast growing, easily to separate from the medium and to dry. They have many silent feature. Biomass production is ordinarily carried out in continuous mode to maximize yields and economic scale. The raw material of this process is very cheap because we used molasses, whey, gas, oil etc. For a substrate. So SCP is waste to best. The molasses and various salts including ammonium and phosphate salt contain of the baker’s yeast. The yeast are used for the production of SCP. The baker’s yeast is useful to as and they create disadvantages also the SCP and baker’s yeast very useful for organism.

[adsense:336x280:8701650588]

ABOUT AUTHOR:
Muhammad Mujahed
M.Sc Biotechnology
Swami Ramanand Teerth Marathwada University, Vishnupuri , Nanded.
mujubiotech2011@rediffmail.com

INTRODUCTION:
A few decades ago, it was realized that certain proteins could be used as pharmaceutical agents for the treatment of human diseases. e.g. insulin for diabetes mellitus, interferon for viral diseases. However the availability of such therapeutic/ pharmaceutical products was limited due to costly and cumbersome procedures involved in their isolation. Further, their use in humans was associated with several complications. For instance, administration of pig insulin to diabetic patients results in the development of antibodies.

The advent of recombinant DNA technology heralded a new chapter for the production of a wide range of therapeutic agents in sufficient quantities for human use. The commercial exploitation of recombinant DNA  (rDNA) technology began in late 1970s by biotechnological companies to produce proteins.There are around 400 different proteins being produced  by rDNAtechnologyand as of now around 30 have been approved for human use.